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tions (2010–present) was employed using key search terms: “meta-analysis” OR “mixed 
treatment comparison” OR “multiple treatments comparison” AND “multiple sclerosis” 
AND (“relapsing remitting” OR “relapsing”). Key aspects of each identified NMA were 
assessed (inclusion/exclusion criteria, model endpoints, model approach, covariates, 
inconsistency tests, and sensitivity analyses) and extracted for analysis. Results: 25 
NMAs were identified (PubMed/Cochrane: 9; scientific congresses: 6; HTA appraisals: 
10). Randomized controlled trial and relapsing-remitting MS were the most frequently 
cited inclusion criteria in the systematic literature reviews. Annualized relapse rate 
was the most frequently reported endpoint, closely followed by proportion of patients 
with disease progression. Most NMAs investigated self-injectable therapies as com-
parator strategies. A frequentist random-effects approach was most commonly used, 
although Bayesian methodology has become more common in recent NMAs. Patient 
and study characteristics were used as covariates in meta-regression; baseline dis-
ease characteristics and publication year significantly impacted results. Consistency 
approaches were not commonly reported; however, when reported, the Bucher method 
was the most common approach used to analyze inconsistency. The majority of NMAs 
did not report sensitivity analyses; however, sensitivity analyses should be performed 
across model methodologies to ensure the robustness of results. ConClusions: 
NMAs provide a valuable means for assessing indirect evidence; however, a critical 
assessment of methodologic approaches is needed when evaluating results.
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objeCtives: This study was conducted to examine the awareness and knowledge 
on oral cancer in a population of Guntur area in South India which could eventually 
aid in the planning of appropriate health promotion. Methods: This is a prospective 
questionnaire based study on 100 subjects, a cross-sectional study was conducted to 
assess the awareness and knowledge of oral cancer including its risk factors, signs 
and symptoms, and beliefs in a population of Guntur area. Results: Oral cancer was 
the least mentioned cancer(68%).There was awareness of the relationship between 
oral cancer and smoking among 98% subjects,but less of the association with alcohol 
misuse (28%).Nonhealing mouth ulcers were identified as a sign or symptom of oral 
cancer by 52% and difficulty in swallowing was selected by 48% subjects.Whereas 88% 
agreed that early detection could improve the treatment outcome,a disheartening 11% 
believed that whether a person developed an oral cancer or not is a matter of luck and 
therefore is unavoidable and 17% subjects do not know .Only 46% subjects have heard 
about oral cancer screening. ConClusions: This survey demonstrates a general lack 
of awareness and knowledge on oral cancer in a population of Guntur area. An oral 
health promotion strategy should involve elements of basic education on oral cancer for 
this population, and regular oral cancer screenings should be implemented in Guntur.
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objeCtive: A challenge in DCEs is to capture how individuals process choices and 
attributes. Chorus, Rose & Hensher (2013) put forth the framework and empirical 
proof that some attributes may be processed using one type of decision rule (e.g., 
random utility maximization-RUM), while others using another rule (e.g., random 
regret minimization-RRM) using the hybrid RUM-RRM modeling approach. This 
study explores if heterogeneity exists in the way community representatives process 
choice attributes while assessing preferences for hemophilia therapies. Methods: 
Representative members of the US general population from the RAND American 
Life Survey panel completed a discrete-choice survey in two waves (N1 = 227; N2= 
344). The survey presented a series of 5 trade-off questions, each including a pair of 
hypothetical treatment profiles and an opt out option. The treatment profiles were 
described using five attributes: 1. costs, 2. dose adjustment, 3. side-effects, 4. effi-
cacy and dosing frequency and 5. type of dosage. Preferences were analyzed using 
RUM, RRM and hybrid RUM-RRM modeling strategies. Models were compared using 
the Ben-Akiva and Swait test for comparison of non-nested models, out of sample 
predictive ability and willingness-to-pay (WTP) estimates. Results: The hybrid 
RRM-RUM models, containing both regret-based and utility-based attribute decision 
rules, outperform choice models where all attributes are assumed to be processed 
by means of one and the same decision rule i.e. either utility maximization or regret 
minimization rule; in terms of model fit (p < 0.01 Ben-Akiva and Swait test) and out-
of-sample predictive ability. The hybrid WTP measures also differ substantially from 
conventional utility-based WTP measures (p< 0.05). ConClusion: The community 
sample processes the ‘cost’ of treatment attribute in order to ‘minimize regret’ while 
other treatment attributes are processed differently in order to ‘maximize utility’.
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objeCtives: Since an estimate of incremental cost-effectiveness ratio (ICER) varies 
depending on a selection of the comparator, decision makers often wonder which 
should be selected, placebo or standard of care (SOC). As the property of extended 
examined for 21 HEOR patient surveys over 10 years. Patients were identified for 
each survey from a large, national administrative claims data base using study-
specific inclusion criteria. Patients were then recruited directly by mail for participa-
tion. Surveys were administered in multiple disease areas including cardiovascular, 
dermatology, digestive, mental health, metabolic/endocrine, musculoskeletal, 
neurology, and respiratory. Survey length, incentive strategy (pre-paid vs. post-
paid), incentive amount, season of administration, and condition type (chronic/
acute) were assessed for impact on RR. Results: Average response rate was 23% 
(SD= 6). Pre-paid incentives were used in 86% of surveys. Mean RR for pre-paid 
incentives was 24% (SD= 6) and 17% (SD= 8) for post-paid incentives, supporting 
existing research on reciprocity garnered through use of pre-paid incentives. A $10 
incentive was used in 2/3 of surveys, $20 in 4 surveys, ≥ $25 in 2 surveys; surveys 
with larger incentive amounts were also longer surveys. RRs were somewhat higher 
with $10 versus ≥ $20 incentives (23% [SD= 6], 20% [SD= 11] respectively). Season of 
administration was correlated with RR. Participants returned surveys administered 
in summer at the highest rate (RR= 24%); RRs for spring administration were lowest 
(21%). Survey length was correlated with RR. RRs were consistently higher for shorter 
(8-9 page) surveys (33%) and were below average for the longest surveys (21%, ≥ 18 
pages). Participants with chronic conditions were more likely to respond (RR= 23% 
[SD= 7] compared to 21% [SD= 4] for acute conditions). ConClusions: Variation 
in RR was seen by season of survey administration, length, and incentive strategy. 
Incentive strategies, both type and amount, remain important considerations, as 
does respondent burden, with lower RRs for acute conditions and longer surveys.
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objeCtives: Several studies have evaluated the extent of pharmacoeconomics 
education in different parts of the world. The objective of this study was to deter-
mine the extent of pharmacoeconomics education in WHO Eastern Mediterranean 
Region schools of pharmacy. Methods: A survey containing questions about 
pharmacoeconomic education was sent to 164 schools of pharmacy in 22 Eastern 
Mediterranean countries via e-mail. Results: Of the 41 (31%) responding schools, 
28 (68%) schools of pharmacy from 12 countries provided some level of pharma-
coeconomics education during the 2012 academic year. The number of classroom 
hours in required courses covering pharmacoeconomics-related topics ranged from 
2 to 60 hours [mean (SD) = 27 (16.8) hours]. ConClusions: The majority of respond-
ing Eastern Mediterranean Region schools of pharmacy offer pharmacoeconomics 
in their curriculum; however, the number of hours and topics dedicated to phar-
macoeconomics varied widely among the schools.
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objeCtives: To investigate the newer Rheumatoid Arthritis (RA) drugs, both 
Tumor Necrosis Factor (TNF) drugs and Disease-Modifying, Anti-Rheumatic Drugs 
(DMARDs), and their comparators (to determine how they correspond to subpopu-
lations). Methods: This study analyzed NICE, HAS, IQWiG, HIS, and SMC Health 
Technology Assessments (HTAs). There were no G-BA reviews of RA during this time. 
The data were exclusively for RA, for the years 2005-2014. The indication under review 
by the HTA body was broken into the following, non-mutually exclusive, categories: 
DMARD-inadequate response (IR) or intolerance, TNF-IR or intolerance, methotrex-
ate naïve, methotrexate-IR or intolerance, and severity. Severity was defined as 
Moderate-to-severe, Severe, and Unspecified. Comparators were consolidated into, 
two non-mutually exclusive, categories: comparators that included biologics and 
comparators that included methotrexate. The category of comparators that included 
methotrexate was then broken into: methotrexate alone or methotrexate with other 
drugs. Results: 77 reviews were included in these analyses. Of those, 46 (60%) used 
methotrexate (either alone or in combination) as a comparator, 21 (27%) exclusively 
used methotrexate as a comparator, and 27 (35%) reviews used the newer biologic 
drugs (either alone or in combination). As a comparator, methotrexate (alone or in 
combination) was significantly associated with both methotrexatenaïve (χ 2= 12.22, 
p= .002, df= 2), and TNF-IR or intolerant (χ 2= 7.61, p= .022, df= 2) subpopulations. Not 
having methotrexate as a comparator (alone or in combination) was nearly evenly 
distributed between the three RA severities: five Moderate-to-severe, four Severe, and 
five Unspecified. Having biologics as a comparator was significantly associated with 
being assessed for DMARD-IR (χ 2= 12.68, p= .002, df= 2) as well as TNF-IR (χ 2= 12.35, 
p= .002, df= 2) subpopulations. ConClusions: Comparators and subpopulations 
appear to be significantly associated among the newest generation of RA medications.
PRM138
A PRAgMAtIC lIteRAtuRe RevIew of netwoRK MetA-AnAlyses of 
dIseAse-ModIfyIng dRugs In the tReAtMent of MultIPle sCleRosIs
Phillips A.L.1, Beckerman R.2, Smith N.J.2, Locklear J.C.1, Jiang Y.2, Solon C.3
1EMD Serono, Inc., Rockland, MA, USA, 2CBPartners, New York, NY, USA, 3CBPartners, San 
Francisco, CA, USA
objeCtives: Numerous network meta-analyses (NMAs) have evaluated disease-
modifying drugs (DMDs) in relapsing multiple sclerosis (RMS) and vary in study 
inclusion criteria, methodology, and statistical analyses. The objective of this study 
was to conduct a pragmatic literature review to identify NMAs of DMDs for the treat-
ment of RMS and to evaluate methodological trends and best practices. Methods: A 
pragmatic literature review of PubMed/Cochrane Library (2000–present), key scientific 
congresses (2010–present), and relevant health technology assessment (HTA) organiza-
